title: Progress of biological agents on psoriatic arthritis.
abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Dashan
authors.initials: D
authors.lastname: Wang
authors.forename: Yantang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Rheumatology, The First Affiliated Hospital of Xiamen University, No.55, Zhenhai Road, Xiamen, Fujian 361003, China. gshi@xmu.edu.cn.
authors.forename: Guixiu
authors.initials: G
authors.lastname: Shi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D001685:Biological Factors / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D001685:Biological Factors; D016207:Cytokines